Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
3
×
boston top stories
dna
3
×
life sciences
national blog main
national top stories
beta-thalassemia
biotech
boston
deals
new york blog main
new york top stories
san francisco blog main
san francisco top stories
achromatopsia
agios therapeutics
azacitidine
base editing
bill cassidy
bluebird bio
branden moriarty
broad institute
cas13
clinical trials
crispr therapeutics
crispr-cas9
dacogen
david liu
decitabine
editas medicine
editor
editr
enzyme
epigenetics
epizyme
farydak
fda
feng zhang
flagship pioneering
fulcrum therapeutics
What
gene
morning
startup
therapeutics
age
aims
approach
based
beam
bigger
biggest
biotech
called
cas
come
crispr
deal
debuts
developing
drugs
editas
editing
editor
emerging
epigenetic
epigenetics
field
flagship’s
founders
gave
gotten
harvard
j
johnson
jump
mass
medicine
medicines
meiragtx
new
Language
unset
Current search:
dna
×
" boston blog main "
×
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M